220010-61-7

Upstream product

• 220010-59-3 N-[3-(3-fluoro-4-thiocarbamoyl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 220010-58-2 N-[[(5S)-3-[3-fluoro-4-nitrile-phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide 
• 220010-60-6 4-[(S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-dithiobenzoic acid methyl ester 

Downstream Products

• 220009-87-0 (S)-N-[[3-[3-Fluoro-4-(1,3,4-thiadiazol-2-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 
• 220010-47-9 (S)-N-[[3-[3-Fluoro-4-[5-[(methylsulfonyl)methyl]-1,3,4-thiadiazol-2-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 
• 1087353-88-5 (S)-N-{3-[4-(5-chloromethyl-[1,3,4]thiadiazol-2-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 
• 1087353-28-3 (S)-N-{3-[3-fluoro-4-(5-[1,2,4]triazol-1-ylmethyl)-[1,3,4]thiadiazol-2-yl-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 

Relevant academic research and scientific papers

NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS

The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents

The synthesis and antibacterial activity of 1,3,4-thiadiazole phenyl oxazolidinone analogues

Replacement of the morpholine C-ring of linezolid 1 with a 1,3,4-thiadiazolyl ring leads to oxazolidinone analogues 5 having potent antibacterial activity against both gram-positive and gram-negative organisms. Conversion of the C5 acetamide group to a thioacetamide further increases the potency of these compounds.